-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trevogrumab in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trevogrumab in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trevogrumab in Obesity Drug Details: Trevogrumab (REGN1033, SAR391786) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nezastomig in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nezastomig in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nezastomig in Renal Cell Carcinoma Drug Details: Nezastomig (REGN-5678) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ubamatamab in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ubamatamab in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ubamatamab in Endometrial Cancer Drug Details: REGN-4018 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mibavademab in Lipodystrophy (Lipoatrophy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mibavademab in Lipodystrophy (Lipoatrophy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mibavademab in Lipodystrophy (Lipoatrophy) Drug Details: Mibavademab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGN-193408 SR in Open-Angle Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGN-193408 SR in Open-Angle Glaucoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGN-193408 SR in Open-Angle Glaucoma Drug Details: AGN-193408 SR is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mibavademab in Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mibavademab in Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mibavademab in Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mibavademab in Acquired Generalized Lipodystrophy (Lawrence Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mibavademab in Acquired Generalized Lipodystrophy (Lawrence Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mibavademab in Acquired Generalized Lipodystrophy (Lawrence Syndrome) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NTLA-2001 in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NTLA-2001 in Familial Amyloid Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NTLA-2001 in Familial Amyloid Cardiomyopathy Drug Details: NTLA-2001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCDARIC-33 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SCDARIC-33 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCDARIC-33 in Refractory Acute Myeloid Leukemia Drug Details: Gene...